IL126319A0 - Eprosartan dihydrate and a process for its production and formulation - Google Patents

Eprosartan dihydrate and a process for its production and formulation

Info

Publication number
IL126319A0
IL126319A0 IL12631997A IL12631997A IL126319A0 IL 126319 A0 IL126319 A0 IL 126319A0 IL 12631997 A IL12631997 A IL 12631997A IL 12631997 A IL12631997 A IL 12631997A IL 126319 A0 IL126319 A0 IL 126319A0
Authority
IL
Israel
Prior art keywords
formulation
production
eprosartan
dihydrate
eprosartan dihydrate
Prior art date
Application number
IL12631997A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL126319(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL126319A0 publication Critical patent/IL126319A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12631997A 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation IL126319A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29
PCT/US1997/004877 WO1997036874A1 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Publications (1)

Publication Number Publication Date
IL126319A0 true IL126319A0 (en) 1999-05-09

Family

ID=21765344

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12631997A IL126319A0 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Country Status (35)

Country Link
EP (1) EP0889880B1 (cs)
JP (1) JP4316013B2 (cs)
CN (2) CN1214682A (cs)
AP (1) AP901A (cs)
AR (1) AR006439A1 (cs)
AT (1) ATE239723T1 (cs)
AU (1) AU726694B2 (cs)
BG (1) BG64095B1 (cs)
BR (1) BR9708336A (cs)
CA (1) CA2250395C (cs)
CZ (1) CZ293345B6 (cs)
DE (1) DE69721749T2 (cs)
DK (1) DK0889880T3 (cs)
DZ (1) DZ2199A1 (cs)
EA (1) EA001958B1 (cs)
EG (1) EG23889A (cs)
ES (1) ES2198564T3 (cs)
HU (1) HU228263B1 (cs)
ID (1) ID16507A (cs)
IL (1) IL126319A0 (cs)
MA (1) MA24437A1 (cs)
MY (1) MY117682A (cs)
NO (2) NO311760B1 (cs)
NZ (1) NZ332008A (cs)
OA (1) OA11176A (cs)
PL (1) PL188816B1 (cs)
PT (1) PT889880E (cs)
RO (1) RO118870B1 (cs)
SK (1) SK282346B6 (cs)
TR (1) TR199801954T2 (cs)
TW (1) TW434239B (cs)
UA (1) UA49880C2 (cs)
UY (1) UY24504A1 (cs)
WO (1) WO1997036874A1 (cs)
ZA (1) ZA972686B (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000383A1 (en) * 1997-06-27 1999-01-07 Smithkline Beecham Corporation Eprosartan monohydrate
EP1033974B1 (en) * 1997-11-17 2014-01-22 GlaxoSmithKline LLC High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
CN1291888A (zh) 1998-03-04 2001-04-18 武田药品工业株式会社 Aⅱ拮抗剂的缓释制剂、其制备和用途
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
NZ509378A (en) * 1998-07-20 2003-04-29 Smithkline Beecham Corp Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
WO2000027396A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
PL196895B1 (pl) * 1999-04-28 2008-02-29 Takeda Pharmaceutical Zastosowanie związku o aktywności antagonistycznej angiotensyny II lub jego soli do wytwarzania kompozycji farmaceutycznej do leczenia lub hamowania rozwoju retynopatii prostej lub retynopatii przed-proliferacyjnej
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
US20040023840A1 (en) * 2000-04-12 2004-02-05 Marc De Gasparo Combination of organic compounds
BR0214383A (pt) * 2001-11-23 2004-11-03 Solvay Pharm Gmbh Tratamento de hipertonia durante a fase aguda do ataque de apoplexia
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
KR20050000556A (ko) * 2002-05-17 2005-01-05 노파르티스 아게 심근 경색증의 속발 예방을 위한 안지오텐신 ｉｉ 수용체차단제 및 베타-차단제의 조합물
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP3045174A1 (en) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
US8361507B2 (en) 2007-07-25 2013-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) * 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
WO1992010189A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
CN1214682A (zh) 1999-04-21
AR006439A1 (es) 1999-08-25
OA11176A (en) 2003-05-13
EP0889880A4 (en) 1999-06-23
AP901A (en) 2000-11-23
DK0889880T3 (da) 2003-09-01
EP0889880A1 (en) 1999-01-13
HK1016594A1 (en) 1999-11-05
NO2002005I1 (no) 2002-09-02
ES2198564T3 (es) 2004-02-01
UA49880C2 (uk) 2002-10-15
EA001958B1 (ru) 2001-10-22
AU2547097A (en) 1997-10-22
HUP9902769A3 (en) 2000-04-28
DZ2199A1 (fr) 2002-12-03
EP0889880B1 (en) 2003-05-07
EG23889A (en) 2007-12-12
DE69721749T2 (de) 2004-03-25
NO984503L (no) 1998-09-28
ZA972686B (en) 1997-09-29
CA2250395A1 (en) 1997-10-09
TW434239B (en) 2001-05-16
MA24437A1 (fr) 1998-10-01
JP4316013B2 (ja) 2009-08-19
NZ332008A (en) 1999-05-28
AP9700956A0 (en) 1997-04-30
SK282346B6 (sk) 2002-01-07
BG64095B1 (bg) 2003-12-31
SK132298A3 (en) 1999-03-12
HUP9902769A2 (hu) 2000-03-28
HU228263B1 (en) 2013-02-28
CN1332167A (zh) 2002-01-23
NO311760B1 (no) 2002-01-21
TR199801954T2 (xx) 1998-12-21
ID16507A (id) 1997-10-02
AU726694B2 (en) 2000-11-16
WO1997036874A1 (en) 1997-10-09
PT889880E (pt) 2003-09-30
UY24504A1 (es) 1997-09-19
BR9708336A (pt) 1999-08-03
EA199800873A1 (ru) 1999-02-25
CZ293345B6 (cs) 2004-04-14
RO118870B1 (ro) 2003-12-30
CA2250395C (en) 2005-09-06
BG102822A (en) 1999-11-30
PL329046A1 (en) 1999-03-01
NO984503D0 (no) 1998-09-28
CZ310198A3 (cs) 1999-03-17
ATE239723T1 (de) 2003-05-15
JP2000508632A (ja) 2000-07-11
MY117682A (en) 2004-07-31
PL188816B1 (pl) 2005-04-29
DE69721749D1 (de) 2003-06-12

Similar Documents

Publication Publication Date Title
EG23889A (en) Eprosartan dihydrate and a process for its production and formulation
HUP9903454A3 (en) A crystalline form of cefditoren pivoxyl and process for the production of the same
IL133195A0 (en) Nonsteroidal gestagen compounds and processes for their production
IL131298A0 (en) A pharmaceutical composition and a process for producing the same
HUP9603112A2 (en) New pharmaceutical formulation and process for its production
IL136831A0 (en) Process for manufacturing bite-dispersion tablets
EP0857484A4 (en) PGE1- FREEZING DRIED PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
HUP0000066A3 (en) Olanzapine dihydrate and process for preparing olanzapine form ii
GB9605597D0 (en) Process for making confectionery
IL125194A0 (en) Process for manufacturing felodipine
IL134378A0 (en) Eprosartan arginyl charge-neutralization- complex and a process for its production and formulation
GB9819651D0 (en) Matrerial and process for its production
PL347658A1 (en) Vancoresmycin, a process for its production and its use as a pharmaceutical
GB2317322B (en) A biscuit manufacturing process
SI0889880T1 (en) Eprosartan dihydrate and a process for its production and formulation
HUP0102370A3 (en) Mumbaistatin, a process for its production and its use as a pharmaceutical
GB9711802D0 (en) Process for confectionery production
GB9602805D0 (en) Production process
HU9701137D0 (en) Process for producing pharmaceutical intermedier
SG78300A1 (en) Production process
GB9607158D0 (en) Process and plant for the production of concrete products
SI1027047T1 (sl) Arginil kompleks eprosartana za nevtralizacijo naboja in postopek za njegovo izdelavo in formulacijo
GB9604097D0 (en) Production process
GB9615770D0 (en) Production process
HU9800144D0 (en) Artifically growed dripstone and process for production thereof

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
FF Patent granted